药品安全无小事。"十四五"期间，国家全方位筑牢药品安全底线，全链条支持医药产业高质量发展，全 覆盖保障人民群众用药需求。跟随这组海报，一起了解下。 》 新华社权威速览 ·非凡"十四五" 全链条支持医药产业高质量发展 批准创新药204个 创新医疗器械265个 我国医药产业规模位居全球第二位 创新药在研数目达到全球的30%左右 批准中药创新药27个 元未 湖 賣 麻 (责任编辑：张紫祎) ...

药品安全无小事。"十四五"期间，国家全方位筑牢药品安全底线，全链条支持医药产业高质量发 展，全覆盖保障人民群众用药需求。跟随这组海报，一起了解下。 新华社权威速览 ·非凡"十四 全方位筑牢药品安全底线 强化覆盖药品全生命周期的动态监管 建立完善药品安全风险会商机制 每年抽检各类药品20余万批次 医疗器械2万余批次 化妆品2万余批次 对国家集采中选产品实行生产企业检查 和中选品种抽检100%全覆盖 新华社权威速览 ·非凡"十四 全链条支持医药产业高质量发 批准创新药204个 创新医疗器械265个 我国医药产业规模位居全球第 创新药在研数目达到全球的30%左右 批准中药创新药27个 文案：黄南希 制作：刘一菲（实习） 策划：令伟家 统筹：曹建礼 ...

Market Regulation & Competition - The State Administration for Market Regulation aims to strengthen the domestic market by improving market regulation systems [1] - The focus is on eliminating local protectionism and market segmentation [1] - The administration intends to address unfair competition, specifically targeting the practice of selling substandard products at low prices [1] Product & Equipment Safety - The plan is to enhance the safety supervision capabilities for food, drugs, industrial products, and special equipment [1] - The goal is to strengthen the entire food safety chain, improve drug safety supervision, and raise the quality and safety standards of industrial products [1] - The administration seeks to improve the quality and effectiveness of special equipment safety supervision [1]

Core Viewpoint - The implementation of drug traceability codes in China aims to enhance drug safety and ensure that all drugs involved in centralized procurement have unique electronic identifiers, thereby preventing counterfeit and substandard drugs from entering the market [1][2]. Group 1: Drug Traceability System - Starting from 2025, all drugs participating in centralized procurement must have traceability codes, which serve as unique electronic identities for each drug package [1]. - The traceability system is designed to provide full-chain transparency in drug management, ensuring that the source, destination, and accountability of drugs can be tracked [2]. - As of February 2025, the National Medical Insurance Information Platform has collected 21.936 billion traceability codes, covering all 31 provinces in China [2]. Group 2: Impact on Drug Safety - The "code-based procurement" approach has effectively reduced drug quality risks and has led to the identification and punishment of illegal activities such as drug reselling and swapping [2]. - The "code-based settlement" mechanism has facilitated precise supervision of medical insurance funds, recovering 27.5 billion yuan in fraudulent claims and identifying 2,008 fraudulent institutions [2]. Group 3: Challenges and Recommendations - Despite advancements, there are still weaknesses in drug safety management, particularly in post-market supervision and the classification of different drug types [3]. - The need for a refined classification and grading management system for various drug types, especially high-risk drugs, is emphasized to prevent treatment failures and adverse reactions [3]. - Recommendations include enhancing the drug traceability system, training specialized personnel, and establishing comprehensive legal frameworks to support the system [5].

Core Points - The new regulation mandates that from July 1, 2023, medical institutions must scan drug traceability codes before settling with medical insurance funds, enhancing drug safety [1] - By January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes, establishing a comprehensive tracking system for pharmaceuticals [1] - The traceability code acts as a unique electronic identity for each drug, ensuring that each box of medication has a single sales record, thus preventing counterfeit and swapped drugs [1] Industry Impact - The integration of drug traceability codes with medical insurance is significant for public drug safety, effectively combating issues like "returned drugs" and fraudulent transactions [2] - The traceability system allows for precise monitoring of high-priced drugs, ensuring they are used appropriately and reach the patients in need [2] - The National Medical Insurance Administration has already demonstrated the effectiveness of this system by investigating the traceability codes of specific drugs, thereby safeguarding both drug safety and insurance funds [2] Public Engagement - Consumers are encouraged to actively participate in ensuring their own drug safety by following six key practices when purchasing medications, including verifying the presence of traceability codes and scanning them for authenticity [3] - The promotion of drug traceability codes is essential, with the goal of making the scanning process a standard practice in every drug transaction [3] - Strengthening regulatory measures around drug traceability codes will help close potential loopholes and enhance public health protection [3]

针对"消费者在石家庄一家医院购买治疗失眠的中药饮剂中含有安眠药"一事，5月19日，石家庄桥西区市场监 督管理局公开通报称，该局就此问题对涉事医院进行立案调查，目前，正在调查之中。 通报称，近日，有媒体报道桥西区河北普泽医养服务有限公司石家庄中医医院生产销售的"中药液"涉嫌添加安 眠药问题，桥西区市场监管局将根据调查结果依法依规进行处置。该局表示，将持续加大药品安全监管力度， 切实保障群众用药安全。 百万用户都在看 证监会重拳出手！3人，被罚没7.5亿元！ 美联储，突爆大消息！ 港股，重大调整！即将实施！ 利好来袭！芯片、特朗普，突传重磅！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 大斌表示，视频发出后有陌生人打来电话表示要联系协商，他未同意。 来源：澎湃新闻、大和报 责编：汪云鹏 校对：赵燕 此前，据大河报报道称，5月17日，网络博主大斌称，一位刘姓消费者通过互联网问诊，在石家庄普泽中医院 购买了治疗失眠的中药饮剂，服用后很快发困，经两家检测机构检测，均含有西药成分地西泮，剩余药剂已经 过公证并封存。 根据《精神药品管理条例》和《精神药品品种目录（2013年版）》，地 ...

Core Viewpoint - A listed company in Shenzhen faced a significant operational impact due to its subsidiary's non-compliance with GMP standards, leading to a production and sales suspension, which resulted in a stock price drop to the daily limit [1] Group 1: Company Impact - The subsidiary generated revenue of 216.57 million yuan and a net loss of 14.00 million yuan in 2024, accounting for 60.09% of the listed company's revenue and 9.8% of its consolidated net profit, indicating a substantial impact on the parent company's operations [1] - The company may face other risk warnings if the subsidiary's production does not resume within three months, as per the Shenzhen Stock Exchange's regulations [1] Group 2: Social Responsibility - Companies in the pharmaceutical sector must prioritize social responsibility and product safety, as the quality of drugs directly affects public health [2] - The concept of "pharmaceutical ethics" should guide the operations of pharmaceutical companies, balancing profit maximization with stakeholder interests [2] Group 3: Recommendations for Improvement - It is recommended that pharmaceutical companies innovate their internal governance by establishing independent quality control committees to oversee production processes and ensure compliance with GMP standards [2] - Companies should enhance their social responsibility disclosures, especially in cases of significant incidents or regulatory actions, to maintain transparency and accountability [3] - The trading rules should be revised to provide clearer criteria for implementing risk warnings, ensuring that the exchange, rather than the company, determines the necessity for such warnings [3] Group 4: Conclusion - Pharmaceutical companies must embed the principle of "quality is life" into their governance structures and operational practices to succeed in both capital markets and public health demands [4]